Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.64 |
| ▸ | DRD3 | P35462 | 8/20 | 0.64 |
| ▸ | DRD4 | P21917 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360233 | 0.85 | DRD2 (0.67) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL2955058 | 0.82 | DRD2 (0.63) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL3217014 | 0.81 | CA1 (0.72) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL14360258 | 0.81 | DRD2 (0.79) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL10357546 | 0.80 | CA1 (0.75) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL31313449 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL17446169 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL30724859 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL1682786 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL1682783 | 0.79 | DRD2 (1.00) | DRD2DRD3DRD4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763751-B2 | Hydroxylamine derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-07-27 | — | — | US | claimed |
| US-20070049643-A1 | Hydroxylamine derivatives | VICURON PHARMACEUTICALS INC. | 2007-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049643-A1 | Hydroxylamine derivatives | C9, C1S, HTT | DRD2 332/4885DRD3 161/4885DRD4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.